When does the Corona Remedies IPO open and close?

The Corona Remedies IPO opens on 8 Dec and closes on 10 Dec.

Where can I check the live subscription status of the Corona Remedies IPO?

You can track the real-time subscription numbers using the links below: https://www.iposcanner.ai/ipo/corona-remedies-ipo?tab=subscription

What is the issue size of the Corona Remedies IPO?

The size of Corona Remedies IPO is Total 61,71,101 shares(aggregating up to ₹655.37 crore) : #Fresh Issue : TBA + #OFS : 61,71,101 shares(aggregating up to ₹655.37 crore).

What is the price band of the Corona Remedies IPO?

The Corona Remedies IPO price band is set between ₹1008-1062 per equity share.

What is the minimum investment for the Corona Remedies IPO?

The minimum investment for the Corona Remedies IPO is ₹14868.

What is the allotment date of the Corona Remedies IPO?

The share allotment date of Corona Remedies IPO is 11 Dec.

What is the Corona Remedies IPO listing date?

The Corona Remedies IPO will be listed on 15 Dec.

How to check Corona Remedies IPO allotment status online?

Follow the steps to check the Corona Remedies IPO allotment status online here: https://www.iposcanner.ai/ipo/corona-remedies-ipo?tab=allotment

Who is the registrar for the Corona Remedies IPO?

The registrar for the Corona Remedies IPO is Bigshare Services Pvt Ltd. You can check your allotment status on their official website.

Corona Remedies IPO Details, GMP, Subscription & Allotment

IPO ScannerIPO Insights

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

Tools

IPO Calendar GMP Tracker Subscription Status Allotment Status

IPOs

All IPOs Live IPOs Upcoming IPOs Closed IPOs Listed IPOs

Resources

eBooks

Company

Home About Us Privacy Policy Terms of Service

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

Want to stay updated?Subscribe to our newsletter

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

Tools

IPO Calendar GMP Tracker Subscription Status Allotment Status

IPOs

All IPOs Live IPOs Upcoming IPOs Closed IPOs Listed IPOs

Resources

eBooks

Company

Home About Us Privacy Policy Terms of Service

About IPO Scanner

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Want to stay updated?Subscribe to our newsletter

About Corona Remedies

.read-more-text__content { display: block !important; overflow: visible !important; -webkit-line-clamp: unset !important; -webkit-box-orient: initial !important; } .read-more-text__toggle { display: none !important; }

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women's healthcare, cardiology, pain management, urology, and other therapeutic areas.The diversified portfolio of the company as of December 2024 comprises 67 brands across therapeutic areas such as women's healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals, including vitamins/minerals/nutrition, gastrointestinal, and respiratory.The company has a pan-India marketing and distribution network with 2,598 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, thus consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.Presently, the company owns two manufacturing facilities located in the states of Gujarat.As of December 31, 2024, the company had 88 R&D employees.

Checklist Quality Analysis

Revenue Growth

Live IPOs

Sotefin Bharat

SME

Open Close16th Jul 2026 - 20th Jul 2026

Issue Size89.76 Cr

Min. Qty600 Shares

Issue Price₹ 178.00

Live IPO

Caliber Mining & Logistics

Mainboard

Open Close17th Jul 2026 - 21st Jul 2026

Issue Size450.00 Cr

Min. Qty35 Shares

Issue Price₹ 402.00

Live IPO

Companies Name	Open - Close	Issue Size	Min. Qty	Issue Price	Apply
Sotefin Bharat SME	16th Jul 2026 - 20th Jul 2026	89.76 Cr	600 Shares	₹ 178.00
Caliber Mining & Logistics Mainboard	17th Jul 2026 - 21st Jul 2026	450.00 Cr	35 Shares	₹ 402.00

See All Live IPOs

Open Date

08 Dec 2025

Close Date

10 Dec 2025

listed

Min Investment

₹14868

Lot Size

14 Shares

Issue Size

₹655.37 Cr

Price Range

₹1008 - ₹1062

Listing Date

Dec 15, 2025

IPO Doc

RHP PDF

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily.

₹302.5(+28.00%)GMP

28.48%Prediction Listing Gain

Grey Market Premium (GMP) Trend

Corona Remedies IPO - Issue Objectives

The IPO is a complete offer-for-sale (OFS). Net IPO proceeds will go to selling shareholders. The company want to achieve the benefits of listing its shares on the stock exchanges.

Carry out the offer for sale

The IPO is a complete offer-for-sale (OFS). Net IPO proceeds will go to selling shareholders.

Listing on stock exchanges

The company want to achieve the benefits of listing its shares on the stock exchanges.

IPO Subscription Status

QIB

293.80x

NII

220.18x

Individual

30.29x

Total

144.49x

Times subscribed by category (bars capped at 10x for readability). Dashed line marks 1.0x (fully subscribed).

Financials of Corona Remedies

In Cr.

Key Performance Indicator	30-Jun-25 (In Cr.)	31-Mar-25 (In Cr.)	31-Mar-24 (In Cr.)	31-Mar-23 (In Cr.)
Revenue	348.56	1202.35	1020.93	891.10
EBITDA	71.80	245.91	161.19	135.03
Expenses
Profit After Tax	46.20	149.43	90.50	84.93
Assets	1012.38	929.86	830.58	595.02
Net Worth	607.02	606.34	480.41	408.52
Reserves	545.86	545.18	419.25	347.36
Borrowing	106.65	62.70	134.14	2.33

Corona Remedies - Promoter(s)

Dr. Kirtikumar Laxmidas Mehta

Niravkumar Kirtikumar Mehta

Ankur Kirtikumar Mehta

Pre Issue Share Holding

72.50%

Post Issue Share Holding

N/A

About Strength & Risks

Strengths5Risks5

Contact Details

Corona Remedies

CORONA House, C – Mondeal Business Park, Near Gurudwara S. G. Highway, Thaltej, Ahmedabad, Gujarat, 380059

+917940233000

[email protected]

https://www.coronaremedies.com/

Registrar Contact Details

Bigshare Services Pvt Ltd

+91-22-6263 8200

[email protected]

https://ipo.bigshareonline.com/ipo_status.html

Corona Remedies IPO - FAQs

Corona Remedies IPO is a Mainboard IPO. The issue is priced at ₹1008-1062 per equity share. The minimum order quantity is 14 Shares. The IPO opens on 8 Dec, and closes on 10 Dec. Bigshare Services Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Growing focus on chronic & sub-chronic therapies

The company has been shifting focus towards categories with longer prescription duration, better patient stickiness, and more profitability. 70.10% of its domestic sales came from chronic/sub-chronic products in MAT June 2025, versus 63.82% in June 2022. This helps ensure recurring revenue and predictable cash flows.

Strong sales infrastructure and deep engagement

The company has built a pan-India commercial engine reaching specialists and super-specialists. ~75.75% of its prescriptions come from specialists vs 60.96% for the broader market, and more than 75% of sales come from urban/semi-urban markets, where purchasing power and compliance are higher.

Trademark protection gaps

Although there are 194 registered trademarks, 67 were opposed / objected / refused / abandoned, and another 29 applications are pending. Some of the engine brands, like Cortel, Argihope, and Dosin, do not have final registrations. In case of similar brand name usage by competitors or any disputes arising, the company could lose brand recognition and revenue.

Heavy dependence on a few therapeutic categories

The company’s product portfolio is concentrated in a limited number of therapeutic categories, such as women's healthcare, cardio-diabeto and pain management therapies. In FY25, these 3 together accounted for 62.40% of total revenue. Any shift in physician prescriptions toward competing alternatives or the launch of viable new alternatives may bring down sales and margins for the company.

Regulatory approvals still pending for the Solan facility

This plant at Solan is one of the major production hubs for the company, but a lot of significant operational approvals are still pending. These include approval for NOC for the extraction of groundwater, authorisation of bio-medical waste, and fire safety NOC. Failure or delay in any of these could lead to forced shutdowns, penalties, or disruptions in production for the company.

About Corona Remedies

Checklist Quality Analysis

Live IPOs

Corona Remedies

Grey Market Premium (GMP) Trend

Corona Remedies IPO - Issue Objectives

Carry out the offer for sale

Listing on stock exchanges

IPO Subscription Status

Financials of Corona Remedies

Corona Remedies - Promoter(s)

About Strength & Risks

Why this IPO looks interesting

Strong portfolio in fast-growing therapeutic areas

Leadership across flagship “engine brands”

Limited exposure to NLEM list

What investors should watch closely

Geographical concentration

Raw material and API supply uncertainty

Contact Details

Registrar Contact Details

Corona Remedies IPO - FAQs

Growing focus on chronic & sub-chronic therapies

Strong sales infrastructure and deep engagement

Trademark protection gaps

Heavy dependence on a few therapeutic categories

Regulatory approvals still pending for the Solan facility

About Corona Remedies

Checklist Quality Analysis

Live IPOs

Corona Remedies

Grey Market Premium (GMP) Trend

Corona Remedies IPO - Issue Objectives

Carry out the offer for sale

Listing on stock exchanges

IPO Subscription Status

Financials of Corona Remedies

Corona Remedies - Promoter(s)

About Strength & Risks

Why this IPO looks interesting

Strong portfolio in fast-growing therapeutic areas

Leadership across flagship “engine brands”

Limited exposure to NLEM list

What investors should watch closely

Geographical concentration

Raw material and API supply uncertainty

Contact Details

Registrar Contact Details

Corona Remedies IPO - FAQs

What is Corona Remedies IPO?

When does the Corona Remedies IPO open and close?

Where can I check the live subscription status of the Corona Remedies IPO?

What is the issue size of the Corona Remedies IPO?

What is the price band of the Corona Remedies IPO?

What is the minimum investment for the Corona Remedies IPO?

What is the allotment date of the Corona Remedies IPO?

What is the Corona Remedies IPO listing date?

How to check Corona Remedies IPO allotment status online?

Who is the registrar for the Corona Remedies IPO?

Growing focus on chronic & sub-chronic therapies

Strong sales infrastructure and deep engagement

Trademark protection gaps

Heavy dependence on a few therapeutic categories

Regulatory approvals still pending for the Solan facility